Recognition of tumor-specific gene products in cancer
AssigneeErasmus Universiteit Rotterdam
InventorsJacobus Johannes Maria van Dongen, Vincent Henricus Johannes van der Velden, Paulus Benjamin Berendes, Adriana Cornelia van Denderen
Life of this patent
Estimating the term…
Abstract
The invention relates to the field of cancer diagnosis and the application of diagnostic techniques in pathology and hematology. Specifically, the invention relates to flow cytometric techniques for the detection of chromosomal aberrations and the detection of tumor specific gene products exclusively expressed by tumor cells containing said chromosomal aberrations. The invention provides a method to detect chromosomal aberrations in a biological sample via the exclusive detection of tumor-specific gene-product using at least two different probes directed against the gene-product.
Claims25
A method of detecting a chromosomal aberration in a biological sample, said method comprising:
- contacting said biological sample with at least two different probes directed against a tumor-specific protein derived from a fused gene under conditions suitable for binding of said probes to said tumor-specific protein, wherein each probe is reactive with a distinct site on said tumor-specific protein;
- and
- detecting by flow cytometry whether said probes bind to said tumor-specific protein, wherein if said probes bind to said tumor-specific protein, the presence of a chromosomal aberration is indicated.
A diagnostic kit for flow cytometric detection comprising at least a first probe and a second probe, said probes directed against a tumor-specific protein derived from a fused gene, wherein said tumor-specific protein is a gene-product of a chromosome having a chromosomal aberration thereon, and wherein each probe is reactive with a distinct site on said tumor-specific protein;
- and means for detecting the tumor-specific protein, wherein at least one of said probes is labeled with a bead.
A method of detecting cancerous cells by flow cytometric detection, comprising:
- providing a biological sample containing cells;
- screening the biological sample for the presence of a chromosomal aberration, said screening comprising detecting a tumor-specific protein derived from a fused gene using at least two different probes directed against the tumor-specific protein, wherein said tumor-specific protein is a gene product of a chromosome having said chromosomal aberration thereon, and wherein each probe is reactive with a distinct site on said tumor-specific protein;
- and
- detecting binding of said at least two different probes to said tumor-specific protein as indicative of the presence of a chromosomal aberration, wherein at least one of said probes is labeled with a bead.
Dependencies are inferred from the claim text.